CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis.

Xin SongChensheng JiangMengli YuChao LuXin-Jue He

Published in: Journal of gastroenterology and hepatology (2024)

CVC significantly inhibited inflammation through CCL5/CCR5 signaling without damaging vital organs and suppressed fibrotic activation in chronic colitis, suggesting its great potential to relieve colonic inflammation and fibrosis.

Keyphrases

oxidative stress
ulcerative colitis
dendritic cells
regulatory t cells
systemic sclerosis
immune response
risk assessment
liver injury
drug induced